Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects

International Journal of Biological Markers

Volumn 28, Issue 2, 2013, Pages 117-130

  Li, Wenzhao ^a   Saji, Shigehira ^a   Sato, Fumiaki ^a   Noda, Makoto ^a   Toi, Masakazu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical trials; Matrix metalloproteinase; Matrix metalloproteinase inhibitor

Indexed keywords

2 [[(4 PHENOXYPHENYL) SULFONYL] METHYL] THIIRANE; 2 [[(4 PHENOXYPHENYL) SULFONYL] METHYL] THIIRANE 40; 2 [N (4 METHOXYSULFONYL) (3 PYRIDINYLMETHYL) AMINO] 3 METHYLBUTYROHYDROXAMIC ACID; 2 [N (4 METHOXYSULFONYL)(3 PYRIDINYLMETHYL)AMINO] 3 METHYLBUTYROHYDROXAMIC ACID; AE 941; ALPHA 2 MACROGLOBULIN; BATIMASTAT; CARBOPLATIN; CISPLATIN; COLLAGENASE; CYTOKINE; DOXYCYCLINE; GELATINASE; GEMCITABINE; GENISTEIN; GI 5712; GROWTH FACTOR; INCYCLINIDE; KB R 8898; KB R 9896; LETROZOLE; MARIMASTAT; MATRILYSIN; MINOCYCLINE; MITOXANTRONE; PACLITAXEL; PLACENTA PROTEIN 5; PREDNISONE; PRINOMASTAT; REBIMASTAT; SMALL INTERFERING RNA; STROMELYSIN; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ZOLEDRONIC ACID;

ADENOCARCINOMA; ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ANOREXIA; ARTICLE; BONE METASTASIS; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; DRUG WITHDRAWAL; ENZYME ACTIVITY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; GLIOBLASTOMA; GLIOMA; HALF LIFE TIME; HEADACHE; HOMEOSTASIS; HUMAN; KAPOSI SARCOMA; KIDNEY CANCER; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT ASCITES; MELANOMA; METASTASIS; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERIODONTITIS; PERITONITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTOXICITY; PLASMACYTOMA; PLEURA EFFUSION; PROSTATE CANCER; PSORIASIS VULGARIS; RASH; RIGIDITY; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR INVASION; VOMITING;

CLINICAL TRIALS AS TOPIC; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; NEOPLASMS;

EID: 84879728129     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000026     Document Type: Article

References (144)

1. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
2. Sato H, Kida Y, Mai M, et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 1992; 7: 77-83.
3. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250.
4. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
5. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27: 5287-97.
6. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-8.
7. Löffek S, Schilling O, Franzke CW. Series "matrix metalloproteinases in lung health and disease": Biological role of matrix metalloproteinases: a critical balance. Eur Respir J 2011; 38: 191-208.
8. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75: 346-59.
9. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-39.
10. Devy L, Dransfield DT. New strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem Res Int 2011; 191-670.
11. Bauer EA, Stricklin GP, Jeffrey JJ, Eisen AZ. Collagenase production by human skin fibroblasts. Biochem Biophys Res Commun 1975; 64: 232-40.
12. Woolley DE, Roberts DR, Evanson JM. Inhibition of human collagenase activity by a small molecular weight serum protein. Biochem Biophys Res Commun 1975; 66: 747-54.
13. Kuettner KE, Hiti J, Eisenstein R, Harper E. Collagenase inhibition by cationic proteins derived from cartilage and aorta. Biochem Biophys Res Commun 1976; 72: 40-6.
14. Cawston TE, Galloway WA, Mercer E, Murphy G, Reynolds JJ. Purification of rabbit bone inhibitor of collagenase. Biochem J 1981; 195: 159-65.
15. Bode W, Fernandez-Catalan C, Grams F, et al. Insights into MMP-TIMP interactions. Ann N Y Acad Sci 1999; 878: 73-91.
16. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-83.
17. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem 1996; 271: 17119-23.
18. Nagase H, Murphy G. Tailoring TIMPs for selective metalloproteinase inhibition. In: The Cancer Degradome, 2008; 787-810.
19. Pavloff N, Staskus PW, Kishnani NS, Hawkes SP. A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J Biol Chem 1992; 267: 17321-6.
20. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 1993; 59: 329-41.
21. Reynolds JJ, Hembry RM, Meikle MC. Connective tissue degradation in health and periodontal disease and the roles of matrix metalloproteinases and their natural inhibitors. Adv Dent Res 1994; 8: 312-9.
22. Clark SD, Kobayashi DK, Welgus HG. Regulation of the expression of tissue inhibitor of metalloproteinases and collagenase by retinoids and glucocorticoids in human fibroblasts. J Clin Invest 1987; 80: 1280-8.
23. Fedak PW, Smookler DS, Kassiri Z, et al. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 2004; 110: 2401-9.
24. Stetefeld J, Jenny M, Schulthess T, et al. The laminin-binding domain of agrin is structurally related to N-TIMP-1. Nat Struct Biol 2001; 8: 705-9.
25. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271: 30375-80.
26. Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, DeClerck YA. Effect of tissue inhibitor of the matrix metalloproteinases- 2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994; 54: 5467-73.
27. Radomski A, Jurasz P, Sanders EJ, et al. Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br J Pharmacol 2002; 137: 1330-8.
28. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, Docherty AJ. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 1991; 30: 8097-102.
29. Willenbrock F, Murphy G. Structure-function relationships in the tissue inhibitors of metalloproteinases. Am J Respir Crit Care Med 1994; 150: S165-70.
30. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001; 276: 12501-4.
31. Fernandez-Catalan C, Bode W, Huber R, et al. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases- 2, the soluble progelatinase A receptor. EMBO J 1998; 17: 5238-48.
32. Tuuttila A, Morgunova E, Bergmann U, et al. Threedimensional structure of human tissue inhibitor of metalloproteinases- 2 at 2.1 A resolution. J Mol Biol 1998; 284: 1133-40.
33. Morgunova E, Tuuttila A, Bergmann U, Tryggvason K. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc Natl Acad Sci U S A 2002; 99: 7414-9.
34. Iyer S, Wei S, Brew K, Acharya KR. Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase- 1. J Biol Chem 2007; 282: 364-71.
35. Maskos K, Lang R, Tschesche H, Bode W. Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2. J Mol Biol 2007; 366: 1222-31.
36. Wisniewska M, Goettig P, Maskos K, et al. Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex. J Mol Biol 2008; 381: 1307-19.
37. Muskett FW, Frenkiel TA, Feeney J, Freedman RB, Carr MD, Williamson RA. High resolution structure of the N-terminal domain of tissue inhibitor of metalloproteinases-2 and characterization of its interaction site with matrix metalloproteinase- 3. J Biol Chem 1998; 273: 21736-43.
38. Williamson RA, Martorell G, Carr MD, et al. Solution structure of the active domain of tissue inhibitor of metalloproteinases- 2. A new member of the OB fold protein family. Biochemistry 1994; 33: 11745-59.
39. Wu B, Arumugam S, Huang W, Brew K, Van Doren SR. 1H, 13C and 15N resonance assignments and secondary structure of the N-terminal domain of human tissue inhibitor of metalloproteinases-1. J Biomol NMR 1999; 14: 289-90.
40. Murzin AG. OB(oligonucleotide/oligosaccharide binding)- fold: common structural and functional solution for nonhomologous sequences. Embo Journal 1993; 12: 861-67.
41. Barrett AJ. Alpha 2-macroglobulin. Methods Enzymol 1981; 80 Pt C: 737-54.
42. Cawston TE, Mercer E. Preferential binding of collagenase to alpha 2-macroglobulin in the presence of the tissue inhibitor of metalloproteinases. FEBS Lett 1986; 209: 9-12.
43. Herman MP, Sukhova GK, Kisiel W, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001; 107: 1117-26.
44. Izumi H, Takahashi C, Oh J, Noda M. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase- 2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett 2000; 481: 31-6.
45. Mott JD, Thomas CL, Rosenbach MT, Takahara K, Greenspan DS, Banda MJ. Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. J Biol Chem 2000; 275: 1384-90.
46. Miyazaki K, Hasegawa M, Funahashi K, Umeda M. A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor. Nature 1993; 362: 839-41.
47. Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107: 789-800.
48. Takahashi C, Sheng Z, Horan TP, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A 1998; 95: 13221-6.
49. Deshane J, Garner CC, Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem 2003; 278: 4135-44.
50. Mannello F, Tonti G, Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005; 5: 285-98.
51. Mannello F. Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon? Recent Pat Anticancer Drug Discov 2006; 1: 91-103.
52. Jiang X, Dutton CM, Qi W, et al. Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma. J Orthop Res 2003; 21: 1063-70.
53. Jiang X, Dutton CM, Qi WN, Block JA, Garamszegi N, Scully SP. siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line. J Cell Physiol 2005; 202: 723-30.
54. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27.
55. Brown PD. Matrix metalloproteinase inhibitors: a new class of anticancer agents. Curr Opin Invest Drugs 1993; 10.
56. Wojtowicz-Praga, Dickson RB, Hawkins JM. Matrix metalloproteinase inhibitors. Investigational New Drugs 1997; 61-75.
57. Macaulay VM, O'Byrne KJ, Saunders MP, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999; 5: 513-20.
58. Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998; 4: 1899-902.
59. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003; 22: 177-203.
60. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997; 75: 69-75.
61. Millar AW, Brown PD, Moore J, et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 1998; 45: 21-6.
62. Rasmussen H, Rugg T, Brown P, Baillet M, Millar A. A 371 patient meta-analysis of studies of marimastat in patients with advanced cancer. In: ASCO Annual Meeting, 1997; Abstr 1538.
63. Zaknoen S, Wolff R, Cox C, et al. Marimastat in advanced progressive colorectal cancer-a dose-finding study. In: ASCO Annual Meeting, 1997; Abstr 968.
64. Malfetano J, Teng N, Barter J, et al. Marimastat in patients with advanced cancer of the ovary-a dose-finding study. In: ASCO Annual Meeting, 1997; Abstr 1331.
65. Boasberg P, Harbaugh B, L, Eisenberger M, et al. Marimastat in patients with hormone refractory prostate cancer: a dose-finding study. In: ASCO Annual Meeting, 1997; Abstr 1126.
66. Rosemurgy A, Harris J, Langleben A, Casper E, Goode S, Rasmussen H. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 1999; 22: 247-52.
67. Evans JD, Stark A, Johnson CD, et al. A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 2001; 85: 1865-70.
68. Steward WP, Thomas AL. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs 2000; 9: 2913-22.
69. Sparano JA, Bernardo P, Stephenson P, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004; 22: 4683-90.
70. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20: 4434-9.
71. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-7.
72. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs 2000; 9: 2167-77.
73. Grochow LB. Preclinical and clinical pharmacology of matrix metalloproteinase inhibitors. Ann Oncol 1998.
74. Goel R, Hirte H, Shah A, et al. Phase I study of the matrix metalloproteinase inhibitor BAY 12-9566. In: ASCO, 1998; Abstr 840.
75. Rowinsky E, Hammond L, Avlesworth C, et al. Prolonged administration of BAY 12-9566, an oral non-peptidic biphenyl matrix: a phase I and pharmacologic study. Ann Oncol 1998; 76a.
76. Hirte H, Vergote IB, Jeffrey JR, et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 2006; 102: 300-8.
77. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3296-302.
78. Hande KR, Collier M, Paradiso L, et al. Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin Cancer Res 2004; 10: 909-15.
79. Hande K, Wilding G, Ripple G, et al. A phase I trial of AG3340, a matrix metalloproteinase inhibitor, in patients having advanced cancer. Ann Oncol 1998; 74a.
80. Bissett D, O'Byrne KJ, von Pawel J, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in nonsmall- cell lung cancer. J Clin Oncol 2005; 23: 842-9.
81. Naglich JG, Jure-Kunkel M, Gupta E, et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001; 61: 8480-5.
82. Levitt NC, Eskens FA, O'Byrne KJ, et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001; 7: 1912-22.
83. Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev 2006; 25: 115-36.
84. Kivelä-Rajamäki M, Maisi P, Srinivas R, et al. Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase- 2) in diseased human peri-implant sulcular fluid. J Periodontal Res 2003; 38: 583-90.
85. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54: 258-65.
86. Syed S, Takimoto C, Hidalgo M, et al. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res 2004; 10: 6512-21.
87. Chu QS, Forouzesh B, Syed S, et al. A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs 2007; 25: 359-67.
88. Vihinen P, Ala-aho R, Kähäri VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005; 5: 203-20.
89. Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 2006; 24: 1389-94.
90. Gu Z, Cui J, Brown S, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005; 25: 6401-8.
91. Krüger A, Arlt MJ, Gerg M, et al. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 2005; 65: 3523-6.
92. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006; 6: 307-12.
93. Li XY, Lin YC, Huang WL, et al. Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells. Med Oncol 2012; 29: 714-20.
94. Mitropoulou TN, Tzanakakis GN, Kletsas D, Kalofonos HP, Karamanos NK. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer 2003; 104: 155-60.
95. Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-57.
96. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001; 28: 620-5.
97. Latreille J, Batist G, Laberge F, et al. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of nonsmall- cell lung cancer. Clin Lung Cancer 2003; 4: 231-6.
98. Huang X, Chen S, Xu L, et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 2005; 65: 3470-8.
99. Kousidou OC, Mitropoulou TN, Roussidis AE, Kletsas D, Theocharis AD, Karamanos NK. Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int J Oncol 2005; 26: 1101-9.
100. Holzbeierlein JM, McIntosh J, Thrasher JB. The role of soy phytoestrogens in prostate cancer. Curr Opin Urol 2005; 15: 17-22.
101. Sonn GA, Aronson W, Litwin MS. Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis 2005; 8: 304-10.
102. Fingleton B. MMPs as therapeutic targets--still a viable option? Semin Cell Dev Biol 2008; 19: 61-8.
103. López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007; 7: 800-8.
104. Konstantinopoulos PA, Karamouzis MV, Papatsoris AG, Papavassiliou AG. Matrix metalloproteinase inhibitors as anticancer agents. Int J Biochem Cell Biol 2008; 40: 1156-68.
105. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011; 278: 28-45.
106. Overall CM, McQuibban GA, Clark-Lewis I. Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biol Chem 2002; 383: 1059-66.
107. Lauer-Fields J, Brew K, Whitehead JK, Li S, Hammer RP, Fields GB. Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors. J Am Chem Soc 2007; 129: 10408-17.
108. Siragam V, Rutnam ZJ, Yang W, et al. MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11. Oncotarget 2012; 3: 1370-85.
109. Mansfield L, Subramanian A, Devalia H, Jiang W, Newbold RF, Mokbel K. HTERT mRNA expression correlates with matrix metalloproteinase-1 and vascular endothelial growth factor expression in human breast cancer: a correlative study using RT-PCR. Anticancer Res 2007; 27: 2265-8.
110. Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007; 446: 765-70.
111. Parsons SL, Watson SA, Steele RJC. Phase I/II trial of batimastat, a matix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Sur Oncol 1997; 23: 526-31.
112. Wojtowicz-Praga S, Low J, Marshall J, et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 1996; 14: 193-202.
113. Wojtowicz-Praga S, Torri J, Johnson M, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998; 16: 2150-6.
114. Tierney GM, Griffin NR, Stuart RC, et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 1999; 35: 563-8.
115. Gradishar W, Sparano J, Cobleigh M, et al. A phase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer. In: ASCO Annual Meeting, 1998; Abstr 548.
116. Adams M, Thomas H. A phase I study of the matrix metalloproteinase inhibitor, marimastat administered concurrently with carboplatin, to patients with relapsed ovarian cancer. In: ASCO Annual Meeting, 1998; Abstr 838.
117. Goffin JR, Anderson IC, Supko JG, et al. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 2005; 11: 3417-24.
118. Larson DA, Prados M, Lamborn KR, et al. Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys 2002; 54: 1397-404.
119. Quirt I, Bodurth A, Lohmann R, et al. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 2002; 20: 431-7.
120. Miller KD, Gradishar W, Schuchter L, et al. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol 2002; 13: 1220-4.
121. Rowinsky EK, Humphrey R, Hammond LA, et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000; 18: 178-86.
122. Hirte H, Goel R, Major P, et al. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12- 9566 administered orally in patients with advanced solid tumours. Ann Oncol 2000; 11: 1579-84.
123. Goel R, Chouinard E, Stewart DJ, et al. An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. Invest New Drugs 2005; 23: 63-71.
124. Hirte H, Stewart D, Goel R, et al. An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin. Invest New Drugs 2005; 23: 437-43.
125. Molina JR, Reid JM, Erlichman C, et al. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs 2005; 16: 997-1002.
126. D'Olimpio J, Hande K, Collier M, Michelson G, Paradiso L, Clendeninn N. Phase I study of the matrix metalloprotease inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors. In: ASCO Annual Meeting, 1999; Abstr 615.
127. Wilding G, Small E, Collier M, Dixon M, Pithavala Y. A phase I pharmacokinetic evaluation of the matrix metalloprotease (MMP) inhibitor AG3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancer. In: ASCO Annual Meeting, 1999; Abstr 1244.
128. Heath EI, Burtness BA, Kleinberg L, et al. Phase II, paralleldesign study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs 2006; 24: 135-40.
129. Levin VA, Phuphanich S, Glantz MJ, et al. Randomized phase II study of temozolomide (TMZ) with and without the matrix metalloprotease (MMP) inhibitor prinomastat in patients (pts) with glioblastoma multiforme (GBM) following best surgery and radiation therapy. In: ASCO Annual Meeting, 2002: Abstr 100.
130. Ahmann FR, Saad F, Mercier R, et al. Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC). In: ASCO, 2001; Abstr 692.
131. Rizvi NA, Humphrey JS, Ness EA, et al. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddasesparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 2004; 10: 1963-70.
132. Brinker BT, Krown SE, Lee JY, et al. Phase 1/2 trial of BMS- 275291 in patients with human immunodeficiency virusrelated Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer 2008; 112: 1083-8.
133. Miller KD, Saphner TJ, Waterhouse DM, et al. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 2004; 10: 1971-5.
134. Lara PN, Stadler WM, Longmate J, et al. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS- 275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 2006; 12: 1556-63.
135. Douillard JY, Peschel C, Shepherd F, et al. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2004; 46: 361-8.
136. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS- 275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 2005; 23: 2831-9.
137. Eatock M, Cassidy J, Johnson J, et al. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother Pharmacol 2005; 55: 39-46.
138. Rudek MA, Figg WD, Dyer V, et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001; 19: 584-92.
139. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002; 20: 153-9.
140. Rudek MA, New P, Mikkelsen T, et al. Phase I and pharmacokinetic study of COL-3 in patients with recurrent highgrade gliomas. J Neurooncol 2011; 105: 375-81.
141. Sauder DN, Dekoven J, Champagne P, Croteau D, Dupont E. Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol 2002; 47: 535-41.
142. Loprinzi CL, Levitt R, Barton DL, et al. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer 2005; 104: 176-82.
143. Escudier B, Choueiri TK, Oudard S, et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 2007; 178: 1901-5.
144. Lu C, Lee JJ, Komaki R, et al. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 2010; 102: 859-65.